WallStSmart

argenx NV ADR (ARGX)vsMilestone Pharmaceuticals Inc (MIST)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

argenx NV ADR generates 252374% more annual revenue ($5.92B vs $2.34M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).

ARGX

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 9.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: 4.92

MIST

Avoid

17

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: -5.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARGXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$2552.01

Current Price

$950.95

$1601.06 discount

UndervaluedFair: $2552.01Overvalued
MISTSignificantly Overvalued (-54.2%)

Margin of Safety

-54.2%

Fair Value

$1.18

Current Price

$0.36

$0.81 premium

UndervaluedFair: $1.18Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARGX6 strengths · Avg: 10.0/10
Return on EquityProfitability
32.8%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
36.3%10/10

Strong operational efficiency at 36.3%

Revenue GrowthGrowth
52.1%10/10

Revenue surging 52.1% year-over-year

EPS GrowthGrowth
50.6%10/10

Earnings expanding 50.6% YoY

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

MIST1 strengths · Avg: 8.0/10
Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

ARGX3 concerns · Avg: 3.0/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
176.8x2/10

Trading at 176.8x book value

MIST4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$86.22M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARGX

The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.

Bull Case : MIST

The strongest argument for MIST centers on Price/Book.

Bear Case : ARGX

The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.

Bear Case : MIST

The primary concerns for MIST are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.79 is elevated, increasing financial risk.

Key Dynamics to Monitor

ARGX profiles as a growth stock while MIST is a value play — different risk/reward profiles.

MIST carries more volatility with a beta of 1.06 — expect wider price swings.

ARGX is growing revenue faster at 52.1% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARGX scores higher overall (73/100 vs 17/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

argenx NV ADR

HEALTHCARE · BIOTECHNOLOGY · USA

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Milestone Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral, Canada.

Visit Website →

Want to dig deeper into these stocks?